A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Recruiting · NCT04573283 · Observational (researchers observe without assigning treatment) · Lead sponsor: Nanfang Hospital, Southern Medical University
View the official record on ClinicalTrials.gov →What this trial is about
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept proposed in 2020. Unlike non-alcoholic fatter liver disease (NAFLD), the diagnosis of MAFLD requires the presence any of the following 3 metabolic risks, including overweight/obesity, presence of diabetes mellitus, and evidence of metabolic dysregulation. However, there are patients that have hepatic steatosis but no metabolic risk, who thus do not meet the diagnostic criteria of MAFLD. Besides, there are patients with both MAFLD and other liver diseases. The clinical features and the management of these patients remain unclear. Thus, further histopathological and clinical study is required to elucidate and compare the characteristics of MAFLD and NAFLD. Here, in this single-center, prospective clinical study, investigators are planning to establish a long-term follow-up cohort of patients with either MAFLD or NAFLD. In order to understand the risk of developing liver-related complications and important extra-hepatic outcomes (e.g. cardiovascular disease), and also to better elucidate the risk of disease progression in "lean" NAFLD individuals without any metabolic dysregulation and MAFLD individuals with dual or multiple causes. Ultimately, investigators aim to improve the diagnosis of MAFLD and improve patients' outcomes.
Who can take part
Inclusion criteria
- Diagnosed as hepatic steatosis in adults (fulfill at least one of the followings):
- Liver ultrasound shows liver parenchymal hyperechoic or "bright liver"
- Controlled attenuation-parameter (CAP) ≥248dB/m
- Hepatic steatosis diagnosed by CT/MRI/MRS
- MRI-based proton-density fat fraction (MRI-PDFF) shows liver fat content\>8%
- Fatty liver confirmed by liver histology.
Exclusion criteria
- Diagnosed with hepatocellular carcinoma or other malignancy (in accordance with the appropriate diagnostic criteria);
- During pregnancy;
- Patients with history of liver transplantation;
- Patients with serious cardiovascular and cerebrovascular events (such as acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.).
Where it is running
1 location listed.
- Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University - Guangzhou, Guangdong, China